2. P N Gadgil Jewellers inability to effectively market its products, or any deterioration in public perception of its brand, could affect consumer footfall and consequently adversely impact its ...

The strength of the brands, P N Gadgil Jewellers uses are crucial to its success. Any reputational damage to the brand, name or logo could have an adverse effect on its financial condition ...

Mukesh Ambani’s company is set to enter the innerwear garment industry through a partnership with the Israeli company Delta Galil. Delta Galil is one of the world’s leading manufacturers of ...

P N Gadgil Jewellers’ shares are trading at a 50% premium in the grey market, an unofficial platform where shares are traded illegally before their official listing. The IPO is being managed by ...

The company's products are primarily sold under its flagship brand, 'PNG', and various sub-brands, through multiple channels, including 39 retail stores (as of July 31, 2024) and various online ...

The P N Gadgil Jewellers IPO is set to raise ₹1,100 crores through the IPO. This includes a fresh issue of ₹850 crores and an offer for sale amounting to ₹250 crores. The IPO will be open ...

P N Gadgil Jewellers, on Monday, said that it has raised ₹330 crore from anchor investors a day before its initial public offerings (IPO) open for subscription on September 9. According to the ...

Pope Francis was joined by more than 10,000 people for a youth festival held at Sir John Guise Stadium in Port Moresby on the final day of his apostolic visit to Papua New Guinea (PNG), reminding ...

The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer ...

But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck executive said — and some analysts agree. “I see these results as important, but preliminary,” Merck ...

Summit Therapeutics’ drug ivonescimab reduced the risk of lung cancer progression or death by nearly half compared to MSD’s blockbuster drug Keytruda (pembrolizumab) in Phase III data showcased on 8 ...